1. Record Nr. UNINA9910830373403321

Autore	Schror Karsten
Titolo	Acetylsalicylic acid / / Karsten Schror
Pubbl/distr/stampa	Weinheim, Germany : , : Wiley-VCH Verlag GmbH & Co. KGaA, , 2016 ©2016
ISBN	3-527-68504-9 3-527-68502-2 3-527-68505-7
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (477 p.)
Disciplina	854.914080356
Soggetti	Aspirin
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	Acetylsalicylic Acid; Contents; Preface; 1: General Aspects; 2: Pharmacology; 3: Toxicity and Drug Safety; 4: Clinical Applications of Aspirin; Appendix 1: Abbreviations; Appendix 2: Selected Clinical Trials and Their Acronyms - Only Published Trials; Index; End User License Agreement; 1.1 History; 1.2 Chemistry; 2.1 Pharmacokinetics; 2.2 Cellular Modes of Action; 2.3 Actions on Organs and Tissues; 3.1 Systemic Side Effects; 3.2 Organ Toxicity; 3.3 Hypersensitivity to Aspirin and Reye's Syndrome; 4.1 Thromboembolic Diseases; 4.2 Pain, Fever, and Inflammatory Diseases 4.3 Further Potential Clinical Indications1.1.1 From Willow Bark to Salicylic Acid; 1.1.2 Synthesis of Acetylated Salicylic Acid and First Medical Use; 1.1.3 Search for Pharmacological Modes of Action; 1.1.4 Clinical Applications: A Piece of History; 1.1.5 Current Research Topics; 1.2.1 Structures and Chemical Properties of Salicylates; 1.2.2 Determination of Salicylates; 2.1.1 Absorption and Distribution; 2.1.2 Biotransformation and Excretion; 2.2.1 Inhibition of Cyclooxygenases; 2.2.2 COX-Independent Actions of Aspirin on Cell Function; 2.2.3 Energy Metabolism 2.3.1 Hemostasis and Thrombosis2.3.2 Inflammation, Pain, and Fever; 2.3.3 Aspirin and Malignancies; 3.1.1 Acute and Chronic Toxicity; 3.1.2 Bleeding Time and Bleeding Risk; 3.1.3 Safety Pharmacology in

Particular Life Situations; 3.2.1 Gastrointestinal (GI) Tract; 3.2.2 Liver; 3.2.3 Kidney; 3.2.4 Audiovestibular System; 3.3.1 Aspirin-Exacerbated Respiratory Disease (AERD, ""Aspirin-Induced Asthma""); 3.3.2 Urticaria/Angioedema and Stevens-Johnson and Lyell's Syndrome; 3.3.3 Reye's Syndrome; 4.1.1 Coronary Vascular Disease; 4.1.2 Cerebrovascular Diseases; 4.1.3 Peripheral Arterial Disease
4.1.4 Venous Thrombosis4.1.5 Preeclampsia; 4.1.6 Aspirin ``Resistance (High On-Aspirin Treatment Platelet Reactivity); 4.2.1 Analgesia and Antipyresis; 4.2.2 Inflammatory Diseases; 4.2.3 Kawasaki's Disease; 4.3.1 Colorectal Cancer; 4.3.2 Alzheimer's Disease; 1.1.1.1 Anti-Inflammatory and Analgesic Effects of Willow Bark and Leaves; 1.1.1.2 Salicylates as the Active Ingredients of Willow Bark and Other Natural Sources; 1.1.1.3 Chemical Synthesis of Salicylic Acid; Summary; References; 1.1.2.1 The Invention of Acetylated Salicylic Acid 1.1.2.2 Introduction of Acetylsalicylic Acid into the ClinicsSummary; References; 1.1.3.1 Salicylates and Energy Metabolism of the Cell; 1.1.3.2 Aspirin and Prostaglandin Formation; 1.1.3.3 Aspirin and COX-2; Summary; References; 1.1.4.1 Anti-Inflammatory/Analgesic Actions; 1.1.4.2 Antiplatelet/Antithrombotic Actions and the Bleeding Tendency; 1.1.4.3 Aspirin and the History of Prevention of Myocardial Infarction and Stroke; Summary; References; 1.1.5.1 Clinical Research; 1.1.5.2 Basic Research; Summary; References; 1.2.1.1 Salicin: The Natural Salicylate; 1.2.1.2 Salicylates in Clinical Use
1.2.1.3 Aspirin Formulations